 Aclaris Therapeutics, Inc. ACRS, a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that it has submitted an Investigational New Drug IND Application to the U.S. Food and Drug Administration FDA for ATI-1777, an investigational topical soft Janus kinase JAK 13 inhibitor, for the treatment of moderate to severe atopic dermatitis AD. We are very pleased to have achieved another development milestone with the submission of this IND and look forward to exploring the therapeutic potential of ATI-1777 in patients with moderate to severe AD, said Dr. David Gordon, Chief Medical Officer of Aclaris. ATI-1777 is designed to be active in the skin but rapidly metabolized in the systemic circulation, with the goal of developing a medicine that is efficacious in the treatment of AD while limiting systemic exposure. 